Sentence examples for heterogeneous trial from inspiring English sources

Results were consistent in a variety of dosage range comparisons and within increasingly heterogeneous trial populations.

Results were consistent across several sensitivity analyses, demonstrating the results' generalizability to a wider more heterogeneous trial population.

Similar results were observed in MAIC sensitivity analyses evaluating other dosage ranges and using more heterogeneous trial populations (e.g., larger randomized sample, broader subject weight range, additional trials).

Sensitivity analyses were conducted, examining different dosage ranges and repeating the analysis in a larger number of trials, allowing for larger and more heterogeneous trial populations.

To determine if the base case results were generalizable to a broader heterogeneous trial population, a second MAIC analysis was conducted where ATX doses ≥1.2 mg/kg/day were compared against three GXR dose cohorts (0.09 0.12, 0.075 0.090, and 0.046 0.075 mg/kg/day).

Results of sensitivity analyses were consistent across a range of GXR doses below the target dose when compared with ATX doses at the target dose or higher, confirming the generalizability of the base case comparison to a broader and more heterogeneous trial population which may be clinically relevant.

In changing medium, engineers use heterogeneous trials to interrogate and address the limitations of an integrated digital model.

Eight trials had data that were extractable for analysis: for four heterogeneous trials with design Ia, the pooled OR was statistically non-significant; collectively for three clinically heterogeneous trials with design Ib, there was a statistically significant SMD favouring adjunctive IHT; in the remaining trial of design 1a, IHT was non-inferior to fluoxetine in the treatment of depression.

Forty-nine trials were classed as 'high risk of bias' and 23 as 'uncertain risk of bias'; the remaining three, clinically heterogeneous, trials displayed sufficiently low risk of bias to be designated reliable evidence.

Heterogeneous trial-level factors are generally easily taken into consideration, but patient-level confounding can be particularly difficult.

Planned contrasts between homogeneous and heterogeneous trials for each condition yielded no significant differences (all P > 0.05).